A
Arvelle Therapeutics
A biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders.
About Arvelle Therapeutics
Arvelle Therapeutics International GmbH, based in Zug, Switzerland, is a biopharmaceutical company focused on developing and commercializing innovative treatments for central nervous system (CNS) disorders. The company's primary product is cenobamate, an investigational anti-seizure medication aimed at treating drug-resistant focal onset seizures in adults. This medication has been designated as a Promising Innovative Medicine (PIM) by the UK's Medicines and Healthcare products Regulatory Agency (MHRA).
Arvelle operates in the European healthcare market, targeting patients suffering from CNS disorders, particularly those with epilepsy who have not responded well to existing treatments. The company collaborates with healthcare professionals (HCPs) and partners like Durbin to ensure the distribution and accessibility of their medication across Europe.
Arvelle's business model revolves around the development, regulatory approval, and commercialization of cenobamate. They generate revenue through the sale of this medication to healthcare providers and institutions. By focusing on a niche market with significant unmet medical needs, Arvelle aims to establish a strong presence in the CNS disorder treatment landscape.
The company actively participates in industry conferences, such as the Jefferies Virtual 2020 Healthcare Conference and the Jefferies 2020 London Healthcare Conference, to present their progress and engage with potential investors and partners. These activities help Arvelle to build credibility and attract the necessary funding to support their ongoing research and development efforts.
In summary, Arvelle Therapeutics is dedicated to bringing new hope to patients with CNS disorders through innovative treatments like cenobamate. Their strategic partnerships and focus on a specialized market position them as a promising player in the biopharmaceutical industry.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 59.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, Woman Founder, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jan 2021 | $960M | $960M | Angelini Pharma | — |
| SERIES AOther financing | May 2020 | $43M | $171M | H.I.G. HealthBridge · NovaQuest Capital Management · Andera Partners · BRV Capital Management | ↗ |
Growth signals
Latest recorded traffic for Arvelle Therapeutics is 390 monthly website visits, up 333.3% over the last three months. Arvelle Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Arvelle Therapeutics in the Zug ecosystem
The Arvelle Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
EQT Life Sciences
NovaQuest Capital Management
BRV Capital Management
HIG Capital
Andera Partners
H.I.G. HealthBridge
F-Prime
Series B and later1 investor entered at this stage
Sio Gene Therapies
Other known investors1 additional known investor
Angelini Pharma
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Arvelle Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Arvelle Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









